Meeting Abstract
Autorenliste: Hart, Christina; Klamroth, Robert; Sachs, Ulrich J.; Greil, Richard; Knoebl, Paul N.; Oldenburg, Johannes; Miesbach, Wolfgang; Pfrepper, Christian; Trautmann-Grill, Karolin; Pekrul, Isabell; Holstein, Katharina; Eichler, Hermann; Weigt, Carmen; Schipp, Dorothea; Werwitzke, Sonja; Tiede, Andreas
Jahr der Veröffentlichung: 2023
Zeitschrift: Blood
Bandnummer: 142
ISSN: 0006-4971
eISSN: 1528-0020
Open Access Status: Bronze
DOI Link: https://doi.org/10.1182/blood-2023-174958
Konferenz: 65th Annual Meeting of the American-Society-of-Hematology (ASH)
Verlag: American Society of Hematology (ASH Publications)
Zitierstile
Harvard-Zitierstil: Hart, C., Klamroth, R., Sachs, U., Greil, R., Knoebl, P., Oldenburg, J., et al. (2023) Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA), Blood, 142. https://doi.org/10.1182/blood-2023-174958
APA-Zitierstil: Hart, C., Klamroth, R., Sachs, U., Greil, R., Knoebl, P., Oldenburg, J., Miesbach, W., Pfrepper, C., Trautmann-Grill, K., Pekrul, I., Holstein, K., Eichler, H., Weigt, C., Schipp, D., Werwitzke, S., & Tiede, A. (2023). Emicizumab Versus Immunosuppression for Acquired Hemophilia. (AHA). Blood. 142. https://doi.org/10.1182/blood-2023-174958
